We are live on ! Find out more
TRVI icon

Trevi Therapeutics
TRVI

55 hedge funds and large institutions have $106M invested in Trevi Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

4% more funds holding

Funds holding: 53 → 55 (+2)

5.03% less ownership

Funds ownership: 81.28% → 76.25% (-5%)

9% less capital invested

Capital invested by funds: $117M → $106M (-$10.6M)

24% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 17

Holders
55
Holders Change
+2
Holders Change %
+3.77%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
13
Reduced
17
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$101K
2
SCM
Silverarc Capital Management
Massachusetts
+$93.7K
3
State Street
State Street
Massachusetts
+$63.3K
4
Deutsche Bank
Deutsche Bank
Germany
+$56.6K
5
Jane Street
Jane Street
New York
+$55.6K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$196K
2
MCM
MAI Capital Management
Ohio
-$188K
3
IAM
Innovis Asset Management
Illinois
-$103K
4
Citadel Advisors
Citadel Advisors
Florida
-$75.4K
5
FFM
Fairmount Funds Management
Pennsylvania
-$61.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$24.8M – – –
FLSM
2
Frazier Life Sciences Management
California
$15M – – –
RCMNY
3
Rubric Capital Management (New York)
New York
$12.4M – – –
FFM
4
Fairmount Funds Management
Pennsylvania
$11.3M -$61.2K -27,073 -0.5%
Viking Global Investors
5
Viking Global Investors
Connecticut
$9.59M – – –
VA
6
VR Adviser
New York
$7.46M – – –
BlackRock
7
BlackRock
New York
$4.68M -$196K -86,598 -4%
Vanguard Group
8
Vanguard Group
Pennsylvania
$4.27M +$101K +44,613 +2%
OM
9
Opaleye Management
Massachusetts
$3.72M +$9.94K +4,400 +0.3%
MCM
10
MAI Capital Management
Ohio
$3.16M -$188K -83,252 -5%
SCM
11
Silverarc Capital Management
Massachusetts
$2.02M +$93.7K +41,491 +5%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.72M +$19.9K +8,819 +1%
State Street
13
State Street
Massachusetts
$1.54M +$63.3K +28,000 +4%
Northern Trust
14
Northern Trust
Illinois
$688K -$13.6K -6,001 -2%
BCM
15
Bridgeway Capital Management
Texas
$407K – – –
TC
16
Tejara Capital
United Kingdom
$393K – – –
JGC
17
J. Goldman & Co
New York
$301K – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
$292K +$5K +2,213 +2%
TCOT
19
Trust Company of Toledo
Ohio
$255K -$17.4K -7,712 -6%
Charles Schwab
20
Charles Schwab
California
$235K – – –
PP
21
PFS Partners
New Jersey
$218K – – –
WA
22
WealthTrust Axiom
Pennsylvania
$204K – – –
Renaissance Technologies
23
Renaissance Technologies
New York
$147K -$49.7K -22,000 -25%
N
24
Nuveen
North Carolina
$146K – – –
RhumbLine Advisers
25
RhumbLine Advisers
Massachusetts
$118K +$9.52K +4,215 +8%
1
2 3

TRVI Hedge Fund Activity: Q3 2023 in Review

55 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q3 2023, worth a combined $106M — down 9% from $117M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TRVI positions and 4 closed out — a net gain of 2 holders — while 13 added to existing stakes and 17 trimmed.

The largest buyer was Vanguard Group, adding an estimated $101K. The largest seller was BlackRock, cutting an estimated $196K.

  • 55 institutional investors held Trevi Therapeutics (TRVI) as of Q3 2023, up from 53 in Q2 2023.
  • Funds reported $106M of Trevi Therapeutics stock for Q3 2023, down 9% quarter-over-quarter.
  • 6 funds opened new Trevi Therapeutics positions in Q3 2023 and 4 closed out, a net change of +2 holders.
  • The largest Trevi Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $101K added.
  • The largest Trevi Therapeutics seller in Q3 2023 was BlackRock, an estimated $196K sold.

Based on aggregated 13F filings for Q3 2023.